Inspired by traditional structure-based algorithms in computer-aided drug design (CADD), we propose the concept of "structure-based Artificial Intelligence Drug Design" .

We are developing a suite of algorithms dedicated to the design, optimization, rapid synthesis, and pharmacokinetic evaluation of small molecule drugs, significantly enhancing the precision and efficiency of drug discovery. Furthermore, we will iteratively train our AI models using large-scale experimental data to improve their accuracy.

Our developed AI-assisted drug design platform stands among the forefront globally in terms of algorithms, equipment, data, models, and applications. It possesses the capability to concurrently support the development of over ten novel drugs in areas including but not limited to anti-coronavirus and anti-cancer therapeutics.